← Leaderboards
Megan M Weivoda
Mayo Clinic Rochester
$4,293,867
Attributed
$6,309,664
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,309,664 · 7
By mechanism
R01$2,555,781 · 2
U01$1,968,418 · 1
R61$694,045 · 1
K01$613,602 · 1
R33$393,490 · 1
F32$84,328 · 1
Top collaborators
- Thomas Levin Geiser Andersen4 shared
- Matthew T Drake4 shared
- Yuji Mishina3 shared
- Dongsu Park3 shared
- Colin Fred Greineder1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Zhenkun Lou$18,569,951
- Matthew T Drake$1,143,985
- Dennis M Black$9,656,727
- Sundeep Khosla$91,221,003
- Samantha R Weaver$682,833
Others in their field
Top investigators on “Bone”
- David Heimbrook · Leidos Biomedical Research, Inc.$240,577,094
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Mary M Horowitz · Medical College Of Wisconsin$136,789,389
- Gregory D Peterson · University Of Tennessee Knoxville$84,527,696
- Richard A Gibbs · Baylor College Of Medicine$64,141,825
- Jeffrey Krischer · University Of South Florida$61,545,982
Research focus
BoneIn VivoIn VitroPreventMediatingMouse ModelExhibitsOsteoporosisBone MassAffectOsteoclastsBone ResorptionOsteogenesisCellsBone LossOsteoblastsAge-Related Bone LossFractureCouplingInnovationAdultEvaluationAmericanBone Marrow
Grant awards (21)
Optimizing bone surface targeting of therapeutic antibodies for osteoporosis$465,663
R01 · FY2025 · AR
Role of senescence in multiple myeloma tumorigenesis$381,504
U01 · FY2025 · AG · contact PI
The impact of age-related changes in osteoclast function on the skeleton$256,399
R01 · FY2025 · AR · contact PI
The impact of age-related changes in osteoclast function on the skeleton$403,708
R01 · FY2024 · AR · contact PI
Role of senescence in multiple myeloma tumorigenesis$394,000
U01 · FY2024 · AG · contact PI
The impact of age-related changes in osteoclast function on the skeleton$453,170
R01 · FY2023 · AR · contact PI
Role of senescence in multiple myeloma tumorigenesis$398,706
U01 · FY2023 · AG · contact PI
A new model for spatio-temporal coupling of bone formation and bone resorption governed by osteoclasts$393,490
R33 · FY2023 · AR
The impact of age-related changes in osteoclast function on the skeleton$481,249
R01 · FY2022 · AR · contact PI
Role of senescence in multiple myeloma tumorigenesis$402,991
U01 · FY2022 · AG · contact PI
The impact of age-related changes in osteoclast function on the skeleton (R01)$495,592
R01 · FY2021 · AR · contact PI
Role of senescence in multiple myeloma tumorigenesis$391,217
U01 · FY2021 · AG · contact PI
A new model for spatio-temporal coupling of bone formation and bone resorption governed by osteoclasts$334,845
R61 · FY2021 · AR
A new model for spatio-temporal coupling of bone formation and bone resorption governed by osteoclasts$359,200
R61 · FY2020 · AR
Osteoclasts Regulate Osteocyte Viability and Function$103,734
K01 · FY2020 · AR · contact PI
Osteoclasts Regulate Osteocyte Viability and Function$126,900
K01 · FY2019 · AR · contact PI
Osteoclasts Regulate Osteocyte Viability and Function$126,900
K01 · FY2018 · AR · contact PI
Osteoclasts Regulate Osteocyte Viability and Function$128,034
K01 · FY2017 · AR · contact PI
Osteoclasts Regulate Osteocyte Viability and Function$128,034
K01 · FY2016 · AR · contact PI
The Role of Podocalyxin in Osteoclast Activity and Bone Metabolism$32,138
F32 · FY2014 · AR · contact PI
The Role of Podocalyxin in Osteoclast Activity and Bone Metabolism$52,190
F32 · FY2013 · AR · contact PI